Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GPR3 | P46089 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448323 | 1.00 | PRNP (0.53) | PRNPRXFP1LMNAMAPK1MCL1 | |
| SCHEMBL9756952 | 0.85 | LMNA (0.46) | PRNPRXFP1LMNAMAPK1MCL1 | |
| SCHEMBL9756955 | 0.85 | LMNA (0.46) | PRNPRXFP1LMNAMAPK1MCL1 | |
| SCHEMBL9556945 | 0.85 | LMNA (0.49) | PRNPRXFP1LMNAMAPK1MCL1 | |
| SCHEMBL31350344 | 0.83 | LIMK1 (0.56) | PRNPRXFP1LMNAMAPK1MCL1 | |
| Hydrochloric Acid SCHEMBL7300365 | 0.81 | LIMK1 (0.54) | PRNPRXFP1LMNAMAPK1MCL1 | |
| SCHEMBL3599532 | 0.80 | LMNA (0.71) | LMNAMAPK1ALDH1A1TDP1KDM4E | |
| SCHEMBL5399193 | 0.79 | LMNA (0.44) | PRNPRXFP1LMNAMAPK1ABCC1 | |
| SCHEMBL6840465 | 0.79 | LMNA (0.41) | PRNPRXFP1LMNAMAPK1MCL1 | |
| SCHEMBL6840468 | 0.79 | LMNA (0.41) | PRNPRXFP1LMNAMAPK1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119421879-A | Novel derivatives for the treatment of TRPM3 mediated disorders | 勒芬天主教大学 | 2025-02-11 | — | — | CN | disclosed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| CN-109475530-B | Aminoacyl indazole immunomodulators for treating autoimmune diseases | 洛克菲勒大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3463341-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2019-04-10 | — | — | EP | disclosed |
| CN-109475530-A | For treating the aminoacyl indazole immunomodulator of autoimmune disease | 洛克菲勒大学 | 2019-03-15 | — | — | CN | disclosed |
| US-9872493-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-23 | — | — | US | disclosed |
| US-9872493-B2 | Method for promoting plant growth | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-23 | — | — | US | disclosed |
| WO-2017205296-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2017-11-30 | — | — | WO | disclosed |
| US-7981904-B2 | Acetyl CoA carboxylase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-19 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2069332-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| EP-1911753-A1 | SPIRO-CYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008020405-A2 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-02-21 | — | — | WO | disclosed |
| US-5189041-A | Gastrointestinal and nervous system disorders, cardiovascular disorders, analgesics | SYNTEX (U.S.A.) INC. (US) | 1993-02-23 | — | — | US | disclosed |
| EP-0485962-A2 | New tricyclic compounds | SYNTEX (U.S.A.) INC. (US) | 1992-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253725-A1 | ACETYL CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | PRNP 4761/4885RXFP1 4107/4885LMNA 2862/4885 |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | PRNP 2737/4885RXFP1 17/4885LMNA 3973/4885 |
| US-20100160255-A1 | SPIRO-CYCLIC COMPOUND | ACACA, CPT1B, PC | PRNP 4872/4885RXFP1 2242/4885LMNA 1022/4885 |
| US-20190202811-A1 | AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI2, IL4I1, TFPI | PRNP 4517/4885RXFP1 4465/4885LMNA 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.